PL1951227T3 - Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca - Google Patents

Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca

Info

Publication number
PL1951227T3
PL1951227T3 PL06829958T PL06829958T PL1951227T3 PL 1951227 T3 PL1951227 T3 PL 1951227T3 PL 06829958 T PL06829958 T PL 06829958T PL 06829958 T PL06829958 T PL 06829958T PL 1951227 T3 PL1951227 T3 PL 1951227T3
Authority
PL
Poland
Prior art keywords
pimobendan
occult
asymptomatic
treatment
heart failure
Prior art date
Application number
PL06829958T
Other languages
English (en)
Inventor
Rainer Kleemann
Christian Troetschel
Andrea Vollmar
Original Assignee
Boehringer Ingelheim Vetmedica Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37744668&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1951227(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Vetmedica Gmbh filed Critical Boehringer Ingelheim Vetmedica Gmbh
Publication of PL1951227T3 publication Critical patent/PL1951227T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL06829958T 2005-11-14 2006-11-08 Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca PL1951227T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05110689 2005-11-14

Publications (1)

Publication Number Publication Date
PL1951227T3 true PL1951227T3 (pl) 2017-09-29

Family

ID=37744668

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06829958T PL1951227T3 (pl) 2005-11-14 2006-11-08 Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca

Country Status (13)

Country Link
US (2) US20070112010A1 (pl)
EP (2) EP3210605A1 (pl)
JP (1) JP5312034B2 (pl)
CN (2) CN102784394A (pl)
AR (1) AR056800A1 (pl)
AU (1) AU2006310997B2 (pl)
CA (1) CA2629367C (pl)
DK (1) DK1951227T3 (pl)
ES (1) ES2631879T3 (pl)
HU (1) HUE033546T2 (pl)
PL (1) PL1951227T3 (pl)
TW (1) TW200735874A (pl)
WO (1) WO2007054514A2 (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
FI20040674A0 (fi) 2004-05-12 2004-05-12 Orion Corp Menetelmä tromboembolisten sairauksien estoon
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
US20110190373A1 (en) * 2008-05-05 2011-08-04 University Of Rochester Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure
US8664252B2 (en) 2008-11-25 2014-03-04 Boehringer Ingelheim Vetmedica Gmbh Phosphodiesterase type III (PDE III) inhibitors or CA2+-sensitizing agents for the treatment of hypertrophic cardiomyopathy
NL1037569C2 (en) * 2009-12-18 2011-06-21 Eurovet Animal Health B V Crystalline pimobendan, process for the preparation thereof, pharmaceutical composition and use.
EP2825159B1 (en) * 2012-03-15 2022-06-22 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
AU2014292086B2 (en) 2013-07-19 2019-08-08 Boehringer Ingelheim Vetmedica Gmbh Preserved etherified cyclodextrin derivatives containing liquid aqueous pharmaceutical composition
EP2925305B1 (en) 2013-12-04 2016-07-27 Boehringer Ingelheim Vetmedica GmbH Improved pharmaceutical compositions of pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease
EA039250B1 (ru) * 2016-06-01 2021-12-23 Бёрингер Ингельхайм Ветмедика Гмбх Применение пимобендана для уменьшения размера сердца и замедления начала клинических симптомов у пациентов с асимптоматической сердечной недостаточностью вследствие митрального порока сердца
WO2022073954A1 (en) 2020-10-08 2022-04-14 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan in the anaesthesia of non-human mammals

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES8101067A1 (es) 1978-08-25 1980-12-01 Thomae Gmbh Dr K Procedimiento para la preparacion de nuevos bencimidazoles sustituidos en posicion 5 o 6 con un anillo de piridazinona
GB8400863D0 (en) * 1984-01-13 1984-02-15 Smith Kline French Lab Chemical compounds
ES2031821T3 (es) * 1985-10-17 1993-01-01 Smith Kline & French Laboratories Limited Procedimiento para preparar derivados de 4(4-oxo-1,4-dihidropiridin-1-il)fenilo.
US4868182A (en) 1986-11-05 1989-09-19 Merrell Dow Pharmaceuticals Inc. Enhancement of prazosin
DE3804490A1 (de) * 1988-02-12 1989-08-24 Heumann Pharma Gmbh & Co Substituierte 6-phenyldihydro-3(2h)-pyridazinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB8824458D0 (en) 1988-10-19 1988-11-23 Orion Yhtymae Oy Substituted pyridazinones
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
DE60237696D1 (de) * 2001-08-01 2010-10-28 Univ Utah Am n-terminus trunkierte isoformen von zyklischen phosphodiesterasen pde3a
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure

Also Published As

Publication number Publication date
EP1951227B1 (en) 2017-04-12
WO2007054514A3 (en) 2007-09-07
US20070112010A1 (en) 2007-05-17
AU2006310997B2 (en) 2013-01-10
JP5312034B2 (ja) 2013-10-09
JP2009515927A (ja) 2009-04-16
HUE033546T2 (hu) 2017-12-28
ES2631879T3 (es) 2017-09-05
DK1951227T3 (en) 2017-07-10
AU2006310997A1 (en) 2007-05-18
EP3210605A1 (en) 2017-08-30
AR056800A1 (es) 2007-10-24
CA2629367A1 (en) 2007-05-18
US20100273807A1 (en) 2010-10-28
CN102784394A (zh) 2012-11-21
CA2629367C (en) 2016-05-03
TW200735874A (en) 2007-10-01
WO2007054514A2 (en) 2007-05-18
CN101309685A (zh) 2008-11-19
EP1951227A2 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
PL1951227T3 (pl) Zastosowania pimobendanu do leczenia bezobjawowej(utajonej) niewydolności serca
HK1116077A1 (en) Roflumilast for the treatment of diabetes mellitus
ZA200806510B (en) Heterobicyclic sulfonamide derivatives for the treatment of diabetes
IL187657A0 (en) Substituted arylpyrazoles for use against parasitites
IL189212A0 (en) Therapeutic agent for diabetes
HK1121438A1 (en) Modified lysine-mimetic compounds
IL177232A0 (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes
GB0518361D0 (en) Therapeutic compounds
EP1970063A4 (en) THERAPEUTIC AGENT AGAINST DIABETES
PL1870409T3 (pl) Związki benzimidazolowe
GB0522881D0 (en) Therapeutic compounds
GB0513812D0 (en) Compounds for imaging and therapy
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
EP1880721A4 (en) MEANS FOR IMPROVING CIRCULAR DISORDER
EP1853274A4 (en) 2-METHYLENE-19-NOR- (20S-24S) -1ALPHA, 25-D HYDROXYVITAMINE-D2
PT1945243E (pt) Utilização da calcitonina para o tratamento da ar
IL191750A0 (en) Imidazole derivatives for the treatment of gastrointestinal disorders
EP1750698A4 (en) 5-ANILINO-4-HETEROARYLPYRAZOLE DERIVATIVES USEFUL FOR THE TREATMENT OF DIABETES
ME01609B (me) Roflumilast za liječenje pulmonarne hipertenzije
HK1097831A1 (en) Benzopyran compounds useful for the treatment of arrhytmia
PL372356A1 (pl) Nowe związki, pochodne kwasu 3-fenylopropionowego
GB0400802D0 (en) Compounds for the treatment of disease
EP1917042A4 (en) USE OF FRUITOSE-BASED COMPOUNDS FOR CANCER DETECTION
IL183036A0 (en) Biomarker for heart failure
ZA200608015B (en) Heteroarylaminopyrazole derivatives useful for the treatment of diabetes